肝细胞癌的血清学诊断——挑战与希望同在

鲁凤民

doi:10.3969/j.issn.1001-5256.2017.07.011

肝细胞癌的血清学诊断——挑战与希望同在

DOI: 10.3969/j.issn.1001-5256.2017.07.011

鲁凤民

北京大学基础医学院病原生物学系

详细信息

中图分类号: R735.7
计量
- 文章访问数: 448
- HTML全文浏览量: 79
- PDF下载量: 252
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-12
- 出版日期: 2017-07-20

Serological diagnosis of hepatocellular carcinoma:challenges and opportunities

Lu FengMin

Department of Pathogenic Biology, School of Basic Medical Sciences, Peking University

摘要

摘要: 血清学指标因无创和操作简易的特点一直是肝细胞癌诊断的研究热点。简要介绍了传统血清学指标AFP在HBV感染相关肝癌辅助诊断和预后预测中的应用。评述了甲胎蛋白异质体（AFP-L3）和异常凝血酶原/脱-γ-羧基凝血酶原（DCP）等新指标的临床应用价值。通过一系列的文献回顾对血清高尔基体蛋白73（GP73）作为肝癌实验室辅助诊断的可能性提出质疑,并依据笔者的实验结果,提出了血清GP73测定或可作为进展期肝纤维化和肝硬化的实验室诊断指标的建议。
- 癌,肝细胞 /
- 肝硬化 /
- 甲胎蛋白类 /
- 甲胎蛋白异质体 /
- 异常凝血酶原 /
- 高尔基体蛋白73
Abstract: Serological markers have the features of noninvasiveness and simple operation and thus have become a research hotspot in the diagnosis of hepatocellular carcinoma.This article briefly introduces the role of the conventional serological marker alpha-fetoprotein (AFP) in assisting the diagnosis and predicting the prognosis of HBV-related liver cancer, as well as the clinical value of new markers such as alpha-fetoprotein-L3 and abnormal prothrombin/des-γ-carboxy prothrombin.Based on literature review, the possibility of serum Golgi protein 73 used for laboratory auxiliary diagnosis of hepatocellular carcinoma has been denied.The results of the author's experiment suggest that serum GP73 measurement can be used as a laboratory diagnostic index for progressive liver fibrosis and liver cirrhosis.
- carcinoma, hepatocellular /
- liver cirrhosis /
- alpha-fetoproteins /
- alpha-fetoprotein-L3 /
- des-gamma-carboxynprothrombin /
- Golgi protein 73

HTML全文

参考文献(26)

[1]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.

[2]EL-SERAG HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J].Gastroenterology, 2012, 142 (6) :1264-1273.

[3]EL-SERAG HB, KANWAL F.Epidemiology of hepatocellular carcinoma in the United States:where are we?where do we go?[J].Hepatology, 2014, 60 (5) :1767-1775.

[4]TREPO C, CHAN HL, LOK A.Hepatitis B virus infection[J].Lancet, 2014, 384 (9959) :2053-2063.

[5]HEYWARD WL, LANIER AP, MCMAHON BJ, et al.Early detection of primary hepatocellular carcinoma.Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus[J].JA-MA, 1985, 254 (21) :3052-3054.

[6]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[7]European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer.EASL-EORTC clinica practice guidelines:management of hepatocellular carcinoma[J].JHepatol, 2012, 56 (4) :908-943.

[8]ZHANG C, CHEN X, LIU H, et al.Alpha fetoprotein mediates HBx induced carcinogenesis in the hepatocyte cytoplasm[J].Int JCancer, 2015, 137 (8) :1818-1829.

[9]YAO MJ, ZHAO JM, LU FM.Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma[J].Oncotarget, 2016, 7 (4) :3702-3708.

[10]YAMAMOTO K, IMAMURA H, MATSUYAMA Y, et al.AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J].J Gastroenterol, 2010, 45 (12) :1272-1282.

[11]NAKAGAWA T, MIYOSHI E, YAKUSHIJIN T, et al.Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients[J].J Proteome Res, 2008, 7 (6) :2222-2233.

[12]JIA ZL, WANG L, LIU C, et al.Clinical significance of alpha-fetoprotein variant in diagnosis of liver cancer[J].China Cancer, 2010, 19 (10) :686-688. (in Chinese) ) 贾志凌, 王莉, 刘畅, 等.甲胎蛋白异质体对肝癌诊断的临床意义[J].中国肿瘤, 2010, 19 (10) :686-688.

[13]HU B, TIAN X, SUN J, et al.Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma:a meta-analysis[J].Int J Mol Sci, 2013, 14 (12) :23559-23580.

[14]YI X, YU S, BAO Y.Alpha-fetoprotein-L3 in hepatocellular carcinoma:a meta-analysis[J].Clin Chim Acta, 2013, 425:212-220.

[15]LIEBMAN HA, FURIE BC, TONG MJ, et al.Des-gammacarboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma[J].N Engl J Med, 1984, 310 (22) :1427-1431.

[16]KIM DY, PAIK YH, AHN SH, et al.PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection[J].Oncology, 2007, 72 (Suppl 1) :52-57.

[17]JI J, WANG H, LI Y, et al.Diagnostic evaluation of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China:a large-scale, multicentre study[J].PLo S One, 2016, 11 (4) :e153227.

[18]LI C, ZHANG Z, ZHANG P, et al.Diagnostic accuracy of desgamma-carboxy prothrombin versusα-fetoprotein for hepatocellular carcinoma:a systematic review[J].Hepatol Res, 2014, 44 (10) :e11-e25.

[19]MAO Y, YANG H, XU H, et al.Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J].Gut, 2010, 59 (12) :1687-1693.

[20]ZHU YW, YAO MJ, LV QJ, et al.Diagnostic evaluation of serum Golgi protein 73 (GP73) for cirrhosis among Chinese chronic hepatitis C patients[J].Hepatol Int, 2017, 11 (Suppl 1) :s1013-s1014.

[21]WANG L, YAO MJ, ZHAO JM, et al.Golgi protein 73:a valuable serum marker for the diagnosis of fibrosis and cirrhosis of non-alcoholic fatty liver disease[J].Hepatol Int, 2017, 11 (Suppl 1) :s60.

[22]YAO MJ, ZHAO JM, LU FM.Serum Golgi protein 73 is not a valuable diagnostic marker for hepatocellular carcinoma[J].Hepatol Int, 2017, 11 (Suppl 1) :s172-s173.

[23]YAO MJ, ZHAO JM, LU FM.Serum Golgi protein 73 is a valuable diagnostic biomarker in HBV infection-related significant fibrosis and early cirrhosis[J].Hepatol Int, 2017, 11 (Suppl 1) :s922-s923.

[24]WANG LJ, LI YM, YAO MJ, et al.Serum Golgi protein 73 is a valuable non-invasive marker for the diagnosis of fibrosis and cirrhosis in patients with autoimmune liver diseases[J].Hepatol Int, 2017, 11 (Suppl 1) :s924-s925.

[25]LI MY, YAO MJ, ZHAO JM, et al.Serum golgi protein 73 values to the early diagnosis of autoimmune liver diseases-related cirrhosis[J].Hepatol Int, 2017, 11 (Suppl 1) :s925.

[26]YAN Y, YAO MJ, ZHAO JM, et al.Diagnostic evaluation of serum golgi protein 73 (GP73) for alcoholic liver cirrhosis among Chinese patients[J].Hepatol Int, 2017, 11 (Suppl 1) :s201-s202.

施引文献

资源附件(0)

访问统计